Search

Abstract submission & Awards

Abstract and Case Report submission is now closed. Abstract awardsIntroduced in 2021 and after 3 editions, we are excited to announce the 4th Emerging Investigators EHA-EBMT Joint Fellowship Awards in the Field of Cell Therapy and Immunotherapy 2024.

Read more

EHA Friends' Fund

Together, we can change the lives of many and make greater strides in the treatment of patients with blood disorders.

Read more

Nobel prize goes to immunotherapy researchers

October 1, Sweden - Cancer kills millions of people every year and is one of humanity’s greatest health challenges.

Read more

EPICOVIDEHA survey

COVID-19 infections in patients with Hematological Malignancies - Results from EHA-IDWP registry
EPICOVIDEHA is an international open web-based registry for patients with haematological malignancies infected with SARS-CoV-2,
The survey has been approved by the Institutional Review Board and Ethics Committee of the…

Read more

Welcome to the EHA2025 Sponsor Program

On this page, you can browse and/or download the interactive EHA2025 Sponsor Program. If the EHA2025 Sponsor Program does not display correctly, please click here or download the file.  

Read more

EU Parliament agrees on pharmaceutical legislation stance

On April 10, the European Parliament adopted its position on the revision of the EU pharmaceutical legislation.

Read more

How malignant cells in patients with Chronic Lymphocytic Leukemia escape T cell recognition and attack

T cell activation is essential for immunity including the recognition and killing of abnormal target cells such as cancerous cells.

Read more

Highlights of Past EHA (HOPE) MENA 2021

For the upcoming edition of the Highlights of Past EHA (HOPE) Middle East and North Africa (MENA), EHA will organize a truly regional meeting by collaborating simultaneously with our hematology partners from the region.

Read more

ATMPs and CAR-T: the uptake challenge

Advanced therapy medicinal products (ATMPs) are a game changer for improving the life of patients with severe to life-threatening diseases. In hematology, for instance, CAR T cell therapy has shown promising results in tackling different blood cancers.

Read more